This site is intended for U.S. healthcare professionals.

Visit Pfizer Medical

Menu

Close

Sign InLog Out
ProductsOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysExplore ContentEventsMaterialsVideosContact
Search

Menu

Close

About ATTR-CMAbout
ATTR-CMDisease ImpactWhen to Rule Out ATTR-CMDiagnosing ATTR-CMAbout VYNDAMAXAbout
VYNDAMAXMortality and Hospitalization6MWT/KCCQ-OS5-year DataHow VYNDAMAX WorksSafety Profile Study DesignDosingAccess & SupportAccess & SupportAccessing VYNDAMAXVyndaLinkResourcesResourcesEventsMaterialsVideos
Prescribing InformationPatient InformationIndication Patient Site
Accessing VYNDAMAXThere are 2 ways for patients to receive their medication once you have prescribed VYNDAMAX

National Specialty Pharmacy
Send your prescription to one of the National Specialty Pharmacies in the defined distribution network.*
See the list here

IDN Specialty Pharmacy, where applicable
Send your prescription to an eligible IDN Specialty Pharmacy.

No matter which pathway you choose, prior authorization (PA) may be needed.
You can also submit a PA request at no cost through www.CoverMyMeds.com

National coverage
  • Nationally, over 2/3 of claims paid by commercially insured patients were $50 or less per month for VYNDAMAX and VYNDAQEL® (tafamidis meglumine)
  • Nationally, more than 90% of Medicare Part D patients have access to VYNDAMAX after meeting applicable PA criteria
  • Nationally, Medicare patients eligible for the Low-Income Subsidy (LIS) program have access to VYNDAMAX for a co-pay of ≤$10.35 per prescription after meeting applicable PA criteria
Pfizer Field Access Specialists are available to provide additional education on how your patients can get access to VYNDAMAX. Ask your Pfizer representative for more information.Co-pay assistance 

Eligible commercially insured patients may pay as little as $0 per month through the VYNDAMAX Co-Pay Savings Program

 Get the card now LoadingTERMS AND CONDITIONS FOR CO-PAY SAVINGS PROGRAM

VYNDAMAX CO-PAY SAVINGS PROGRAM TERMS AND CONDITIONS​​​​​​

By using this co-pay card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Patients are not eligible to use this card if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico.
  • Patient must have private insurance. Offer is not valid for cash-paying patients. Patients are responsible for as little as a $0 monthly co-payment based upon program utilization. The value of this co-pay card is limited to a maximum of $60,000 per calendar year.
  • This co-pay card is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this co-pay card from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the co-pay card to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the co-pay card, as may be required. You should not use the co-pay card if your insurer or health plan prohibits use of manufacturer co-pay cards.
  • You must be 18 years of age or older to redeem the co-pay card.
  • This co-pay card is not valid where prohibited by law.
  • Co-pay card cannot be combined with any other savings, free trial, or similar offer for the specified prescription.
  • Co-pay card will be accepted only at participating pharmacies.
  • This co-pay card is not health insurance.
  • Offer good only in the U.S. and Puerto Rico.
  • Co-pay card is limited to 1 per person during this offering period and is not transferable.
  • A co-pay card may be redeemed for either a VYNDAMAX or VYNDAQEL prescription, but not more than once per 24 days per patient.
  • No other purchase is necessary.
  • No membership fee.
  • Data related to your redemption of the co-pay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other co-pay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  • Offer expires 12/31/2023.
For more information, visit our website www.VyndaLink.com,
call 1-888-222-8475, or write:
Pfizer, ATTN: Claims Processing Department, IQVIA, Inc., 77 Corporate Drive, Bridgewater, NJ 08807 Next: See how VyndaLink can help support your patients throughout treatment Continue Loading
Access to VYNDAQEL® (tafamidis meglumine) is available through the same defined distribution network. IDN=integrated delivery network.
Access & Support
Access resources for you and your patient Explore resources Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2024 Pfizer Inc. All rights reserved.

PP-VDM-USA-1664
You are now leaving Pfizer You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.

PP-VDM-USA-0908
INDICATION AND LIMITATIONS OF USE VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.Please see Full Prescribing Information including Patient Information.
Important Safety InformationAdverse Reactions
In studies in patients with ATTR-CM, the frequency of adverse events in patients treated with VYNDAQEL® (tafamidis meglumine) was similar to placebo.

Specific Populations

Pregnancy: Based on findings from animal studies, VYNDAQEL and VYNDAMAX may cause fetal harm when administered to a pregnant woman.

Lactation: There are no available data on the presence of tafamidis in human milk, the effect on the breastfed infant, or the effect on milk production. Tafamidis is present in rat milk. When a drug is present in animal milk, it is likely the drug will be present in human milk. Breastfeeding is not recommended during treatment with VYNDAQEL and VYNDAMAX.IndicationVYNDAQEL® (tafamidis meglumine) and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Please see Full Prescribing Information including Patient Information.